![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 49, 47136-47148, December 6, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Human immunodeficiency virus, type 1 (HIV-1)
infection of CD4+ T cells progressively abrogates T
cell receptor (TCR)·CD3 function and surface expression by
specifically interfering with CD3
Identification of Three NFAT Binding Motifs in the
5'-Upstream Region of the Human CD3
Gene That
Differentially Bind NFATc1, NFATc2, and NF-
B p50*
,
, and
¶
Laboratory of Experimental Hematology,
Faculty of Medicine, University of Brussels, 121 Blvd. de Waterloo,
Brussels B1000, Belgium and the § Division of Infectious
Diseases, Department of Medicine, Northwestern University Medical
School, Chicago, Illinois 60611
gene transcription. Our data show that the loss of CD3
transcripts begins very early after infection and accumulates to a
>90% deficiency before a significant effect on surface receptor
density is apparent. Blocking TCR·CD3-directed NFAT activation with
cyclosporin A provokes a partial re-expression of CD3
gene transcripts and surface complexes in a time- and
dose-dependent manner. We have identified three NFAT
consensus sequences (5'-GGAAA-3') in the 5'-upstream region of the
human CD3
gene at:
124 to
120
(NFAT
1),
384 to
380 (NFAT
2), and +450
to +454 (NFAT
3) from the first transcription initiation
site. Using electrophoretic mobility shift and supershift assays, we
show that NFATc2 alone binds to the NFAT
2 motif;
however, complexes containing either NFATc2 or NFATc1 plus NF-
B p50
bind to the NFAT
1 and NFAT
3 sites. We
further demonstrate that NFATc1 and NF-
B p50 bind in the same
protein·DNA complex and that a fourth Ala added to the core sequence
(5'-GGAAAA-3') in NFAT
1, and
NFAT
3 is critical for their binding. Finally, we have
shown that an increase in the binding of nuclear NFATc2, NFATc1, and
NF-
B p50 to these three motifs is correlated with a progressive loss
of CD3
transcripts after HIV-1 infection.
*
This work was supported by grants from the Belgian Fonds
National de la Recherche Scientifique (FNRS-FRSM Grant 3.4584.01 and
FNRS-Télévie Grants 7.4554.01 and 7.4584.01), the European Commission (Grant QLK2-2000-01040), the National Institutes of Health
(Grant HD37356), and a collaborative grant from the International Brachet Foundation (Grant R 97/8-05).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
This article has been cited by other articles:
![]() |
Y. Tone, Y. Kojima, K. Furuuchi, M. Brady, Y. Yashiro-Ohtani, M. L. Tykocinski, and M. Tone OX40 Gene Expression Is Up-Regulated by Chromatin Remodeling in Its Promoter Region Containing Sp1/Sp3, YY1, and NF-{kappa}B Binding Sites J. Immunol., August 1, 2007; 179(3): 1760 - 1767. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Cardoso, V. Durbecq, J.-F. Laes, B. Badran, L. Lagneaux, F. Bex, C. Desmedt, K. Willard-Gallo, J. S. Ross, A. Burny, et al. Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner Mol. Cancer Ther., December 1, 2006; 5(12): 3042 - 3051. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. M. Badran, K. Kunstman, J. Stanton, M. Moschitta, A. Zerghe, H. Akl, A. Burny, S. M. Wolinsky, and K. E. Willard-Gallo Transcriptional Regulation of the Human CD3{gamma} Gene: The TATA-Less CD3{gamma} Promoter Functions via an Initiator and Contiguous Sp-Binding Elements J. Immunol., May 15, 2005; 174(10): 6238 - 6249. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |